AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact

AstraZeneca is paying $85 million to kick off an alliance with Quell Therapeutics focused on developing new cell therapies for autoimmune diseases. Type 1 diabetes and inflammatory bowel disease are the focus of research collaboration.